O'Shaughnessy Ventures Funds AI-Powered Home Clinical Trial Platform
Event summary
- O'Shaughnessy Ventures awarded a $100,000 fellowship to Fengyi Zheng on April 2, 2026.
- Zheng will use the funds to develop BioMe, an AI-powered platform for at-home motor function assessments in clinical trials.
- BioMe aims to replace subjective in-clinic evaluations with objective, consistent data from home-recorded videos.
- Zheng previously researched CRISPR technology at the Broad Institute and developed a working prototype using open-source computer vision models.
The big picture
O'Shaughnessy Ventures' backing of BioMe reflects growing investment in decentralized clinical trials, driven by demand for more inclusive participant pools and objective data collection. The $100,000 fellowship is part of OSV's broader strategy to support innovative healthcare technologies that address systemic biases in medical research.
What we're watching
- Adoption Pace
- How quickly BioMe can gain acceptance among clinical trial sponsors and regulatory bodies.
- Data Quality
- Whether AI-powered home assessments can match or exceed the reliability of traditional in-clinic evaluations.
- Market Expansion
- The pace at which BioMe can expand beyond motor function assessments to other clinical trial applications.
Related topics